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Q Fever  
Endocarditis and 
New Coxiella  
burnetii Genotype, 
Saudi Arabia
To the Editor. Q fever is a world-
wide zoonosis caused by an obligate 
intracellular bacterium, Coxiella bur-
netii (1). Q fever endocarditis is as-
sociated with surgery for 15%–73% 
of patients, causes death for 5%–65% 
of patients, and induces a large num-
ber of relapses when the endocarditis 
is inadequately treated (1). The most 
serious risk factor for endocarditis is 
a substantial underlying valvulopathy, 
but progression to endocarditis is 
also found in patients with clini-
cally silent, previously undiagnosed, 
valvulopathies (1). Since the 1960s, Q 
fever has been recognized as a public 
health problem in Saudi Arabia, and 
studies have shown that coxiellosis 
occurs in livestock (2,3). Only a few 
cases of Q fever endocarditis in Saudi 
Arabia have been reported (4–6). We 
report 2 new cases of Q fever endo-
carditis and detection of a new C. bur-
netii genotype in this country.
The first case was detected in 2007 
in a 45-year-old man in Saudi Arabia 
who had fever, pneumonia, and asthe-
nia. A transesophageal echocardiogram 
showed endocarditis. Results of an im-
munofluorescence assay were positive 
for C. burnetii; phase I titers for IgG, 
IgM, and IgA were 51,200, 100, and 
25, respectively, and phase II titers were 
102,400, 200, and 50, respectively. Se-
rum and blood samples were negative 
for C. burnetii by real-time PCR for the 
IS1111 and the IS30A spacers (7). For 
each sample, the quality of DNA extrac-
tion was verified by real-time PCR for 
a housekeeping gene encoding β-actin 
(7). The aortic valve was surgically re-
placed, and C. burnetii–specific PCR 
results for the valve were positive. Ac-
cording to multispacer sequence typing 
(8), this C. burnetii isolate was a new 
genotype, MST51 (Figure). A C. bur-
netii isolate was cultured from the valve 
of this patient by the shell-vial method 
that used human embryonic lung cells 
(7). IgG anticardiolipin testing results 
were negative (9). The patient was 
given 200 mg oral doxycycline daily 
and 200 mg oral hydroxychloroquine 3 
times daily for 18 months.
The second case was detected in 
2012 in a 13-year-old boy in Saudi 
Arabia who had tetralogy of Fallot, a 
prosthetic pulmonary valve, 2 intra-
cardiac stents, and long-term fever. 
Serologic testing results were posi-
tive for C. burnetii; phase I titers for 
IgG, IgM, and IgA were 51,200, 400, 
and 200, respectively, and phase II ti-
ters were 102,400, 800, and 400, re-
spectively. Whereas serum and blood 
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samples were negative for C. burnetii 
by real-time PCR for the IS1111 and 
the IS30A spacers, the β-actin control 
was positive (cycle threshold <30). 
For this patient, we did not receive any 
material for culture. The patient was 
given 200 mg oral doxycycline daily 
and 200 mg oral hydroxychloroquine 
3 times daily for 18 months.
To the best of our knowledge, 
before the 2 cases presented here, 
only 3 cases of Q fever endocarditis 
in Saudi Arabia have been described; 
all patients were from rural regions of 
Saudi Arabia and had an underlying 
valvulopathy (4–6). Moreover, Q fe-
ver was not immediately suspected, 
and as a result, 1 patient died (6). 
However, for 2 other patients, valve 
replacement was necessary (4,5). Q 
fever is prevalent in Saudi Arabia, 
and the very high prevalence of Q 
fever among camels was proposed as 
the reason Q fever is endemic among 
humans in Saudi Arabia (2,3). Cam-
els were also suspected as the prob-
able source of acute Q fever in US 
soldiers returning from Saudi Arabia 
(10). We identified a new C. bur-
netii genotype in the aortic valve of 
the first patient reported here. More 
epidemiologic studies are needed to 
determine whether this novel geno-
type circulating in Saudi Arabia is 
endemic to Saudi Arabia and wheth-
er it plays a major role in the origin 
of Q fever and in public health in 
this country.
Our studies of Q fever cases in 
southern France have shown that 
>16% of patients with acute Q fever 
have endocarditis and that ≈16% 37% 
of patients with Q fever endocarditis 
could have had previous symptom-
atic acute Q fever infection (1). Thus, 
many cases of endocarditis might be 
avoided if patients with acute Q fever 
receive antimicrobial drugs as pro-
phylaxis (1). For patients >40 years of 
age, transthoracic echocardiography 
should be performed because of the 
increased prevalence of valvulopathy 
and Q fever endocarditis in this popu-
lation (9). As a result, more studies are 
needed to determine whether our data 
can affect local clinical practice.
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Lack of MERS  
Coronavirus but 
Prevalence of  
Influenza Virus in 
French Pilgrims  
after 2013 Hajj
To the Editor: Saudi Arabia has 
reported the highest number of Middle 
East respiratory syndrome coronavirus 
(MERS-CoV) cases since the virus first 
emerged in 2012, with >127 confirmed 
cases and a case-fatality rate of 42%, as 
of November 2013 (1). Global attention 
has focused on the potential for spread 
of MERS-CoV after the Hajj pilgrim-
age during which Muslims from 180 
countries converge in Mecca, Saudi 
Arabia. Such pilgrims have a high risk 
for respiratory tract infections because 
of severe overcrowding. The Interna-
tional Health Regulations Emergency 
Committee advised all countries (par-
ticularly those with returning pilgrims) 
to strengthen their surveillance capaci-
ties and ensure robust reporting of any 
identified cases (2).
We report the results of a prospec-
tive cohort study conducted in Saudi 
Arabia in October 2013. Participants 
in the survey were adult Hajj pilgrims 
who traveled together in a group 
(through 1 travel agency in Marseille, 
France) from October 3 through Octo-
ber 24, 2013. Pilgrims were included 
in the study on a voluntary basis and 
were asked to sign a written consent 
form. All pilgrims received advice 
about individual prevention mea-
sures against respiratory tract infec-
tion before departing, and follow-up 
was conducted during the journey 
by a medical doctor who systemati-
cally documented travel-associated 
diseases. Nasal swab specimens were 
obtained just before the pilgrims left 
Saudi Arabia, frozen <48 hours after 
sampling, and processed (3,4). Each 
sample was tested for MERS-CoV 
(upE and ORF1a genes) (5,6) and in-
fluenza A, B (7), and A/2009/H1N1 
viruses (8) by real-time reverse tran-
scription PCR. The protocol was ap-
proved by our Institutional Review 
Board (July 23, 2013; reference no. 
2013-A00961–44) and by the Saudi 
Ministry of Health ethics committee. 
On departure from France, the 
study comprised 129 pilgrims. Their 
mean age was 61.7 years (range 34–85 
years), and the male/female ratio was 
0.7:1. Sixty-eight (52.7%) pilgrims 
reported having a chronic disease, 
including hypertension (43 [33.3%]), 
diabetes (34 [26.4%]), chronic cardiac 
disease (11 [8.5%]), and chronic re-
spiratory disease (5 [3.9%]). Forty-six 
(35.7%) pilgrims reported receiving 
influenza vaccination in 2012; none 
had been vaccinated in 2013 before 
the Hajj because the vaccine was not 
yet available in France.
Clinical data were available for 
129 persons: 117 (90.7%) had respira-
tory symptoms while in Saudi Arabia, 
including cough (112 [86.8%]) and 
sore throat (107 [82.9%]); 64 (49.6%) 
reported fever, and 61 (47.3%) had 
conditions that met the criteria for 
influenza-like illness (ILI; i.e., the as-
sociation of cough, sore throat, and 
subjective fever) (Figure) (4). One 
patient was hospitalized during travel 
(undocumented pneumonia). Nasal 
swab specimens were obtained from 
129 pilgrims on October 23, 2013 
(week 43), 1 day before pilgrims left 
Saudi Arabia for France; 90 (69.8%) 
pilgrims were still symptomatic. All 
PCRs were negative for MERS-CoV.
Eight pilgrims tested positive for 
influenza A(H3N2), 1 for influenza 
A(H1N1), and 1 for influenza B vi-
rus. No dual infections were reported. 
70 (54.3%) pilgrims were seen 3–5 
weeks after they returned to France, 
and the remaining were lost to follow-
up. Fifty-five (78.6%) had experienced 
respiratory symptoms since their re-
turn, including cough (50 [71.4%]) and 
sore throat (14 [20.0%]); 12 (17.1%) 
reported fever, and illness in 5 (7.1%) 
pilgrims met the criteria for ILI. 
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